Effects of Hibiscus sabdariffa extract powder and preventive treatment (diet) on the lipid profiles of patients with metabolic syndrome (MeSy).
ABSTRACT Insulin resistance, obesity, hypertension, and dyslipidemia are strongly associated with metabolic syndrome (MeSy), which is considered to be a reversible clinical stage before its evolution to coronary heart disease and diabetes. Currently, the antihypertensive and hypolipidemic properties of aqueous Hibiscus sabdariffa extracts (HSE) have been demonstrated in clinical trials and in vivo experiments. The aim of the present study was to evaluate the effects of a Hibiscus sabdariffa extract powder (HSEP) and a recognized preventive treatment (diet) on the lipid profiles of individuals with and without MeSy according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) criteria. The protocol was a follow-up study carried out in a factorial, randomized design (T1=preventive treatment comprises Diet, T2=HSEP, T3=HSEP+preventive treatment (Diet) X MeSy, non-MeSy individuals). A total daily dose of 100 mg HSEP was orally administered in capsules for one month. The preventive treatment (diet) was selected according to NCEP-ATP III recommendations and adjusted individually. Total cholesterol, LDL-c, HDL-c, VLDL-c, triglycerides, glucose, urea, creatinine, AST, and ALT levels in the blood were determined in all individuals pre- and post-treatment. The MeSy patients treated with HSEP had significantly reduced glucose and total cholesterol levels, increased HDL-c levels, and an improved TAG/HDL-c ratio, a marker of insulin resistance (t-test p<0.05). Additionally, a triglyceride-lowering effect was observed in MeSy patients treated with HSEP plus diet, and in individuals without MeSy treated with HSEP. Significant differences in total cholesterol, HDL-c, and the TAG/HDL-c ratio were found when the means of absolute differences among treatments were compared (ANOVA p<0.02). Therefore, in addition to the well documented hypotensive effects of Hibiscus sabdariffa, we suggest the use of HSEP in individuals with dyslipidemia associated with MeSy.
- SourceAvailable from: Trinovita Andraini[Show abstract] [Hide abstract]
ABSTRACT: Abstrak Latar belakang: Dislipidemia dan stres oksidatif memiliki peran penting sebagai penyebab resistensi insulin. Salah satu herba yang memiliki efek antioksidan kuat dan dapat memperbaiki dislipidemia adalah Hibiscus sabdariffa Linn. Penelitian ini bertujuan mengetahui efek ekstrak Hibiscus sabdariffa Linn. terhadap kadar glukosa darah puasa, kadar insulin darah puasa dan indeks resistensi insulin (HOMA-IR) pada tikus yang diberi diet tinggi fruktosa. Metode: Penelitian eksperimental in vivo ini dilakukan pada 25 tikus Sprague-Dowley yang diberi diet tinggi fruktosa (10% ad libitum) bersamaan dengan pemberian ekstrak Hibiscus sabdariffa Linn. pada dosis 100, 200 dan 400 mg/kgBB/hari selama 5 minggu. Pada akhir penelitian dilakukan pengukuran kadar glukosa darah puasa, kadar insulin puasa, dan indeks resistensi insulin (HOMA-IR). Hasil: Kadar glukosa darah puasa, kadar insulin darah puasa, dan HOMA-IR pada kelompok tikus yang diberi diet tinggi fruktosa bersamaan dengan Hibiscus sabdariffa Linn. pada dosis 100 mg/kgBB/hari tidak berbeda bermakna dibandingkan kelompok tikus yang hanya diberikan diet tinggi fruktosa sedangkan pada dosis 400 mg/kgBB/hari lebih rendah secara bermakna dibandingkan pada kelompok tikus yang hanya diberi diet tinggi fruktosa (masing-masing 4,84 mmol/L vs 6,11 mmol/L, 0,07 µU/L vs 0,3 µU/L, dan 0,02 vs 0,08).Medical Journal of Indonesia 01/2014;
- [Show abstract] [Hide abstract]
ABSTRACT: Hibiscus sabdariffa L. (Hs, roselle; Malvaceae) has been used traditionally as a food, in herbal drinks, in hot and cold beverages, as a flavouring agent in the food industry and as a herbal medicine. In vitro and in vivo studies as well as some clinical trials provide some evidence mostly for phytochemically poorly characterised Hs extracts. Extracts showed antibacterial, anti-oxidant, nephro- and hepato-protective, renal/diuretic effect, effects on lipid metabolism (anti-cholesterol), anti-diabetic and anti-hypertensive effects among others. This might be linked to strong antioxidant activities, inhibition of α-glucosidase and α-amylase, inhibition of angiotensin-converting enzymes (ACE), and direct vaso-relaxant effect or calcium channel modulation. Phenolic acids (esp. protocatechuic acid), organic acid (hydroxycitric acid and hibiscus acid) and anthocyanins (delphinidin-3-sambubioside and cyanidin-3-sambubioside) are likely to contribute to the reported effects. More well designed controlled clinical trials are needed which use phytochemically characterised preparations. Hs has an excellent safety and tolerability record.Food Chemistry 12/2014; · 3.26 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Panax ginseng is a famous traditional medicine in Korea for its beneficial effect on obesity, cardiac and liver associated diseases. The aim of this study was to investigate the metabolite in Panax ginseng (P. ginseng, Aralicaceae) berries depending on the ripen stages and evaluate its potential inhibition on adipocyte differentiation in 3 T3-L1 cells. Different ripening stage samples of P. ginseng berry were analyzed through global metabolite profiling by NMR spectroscopy. Lipid accumulation in the cells was analyzed by Oil Red O staining. The PLS-DA clearly distinguished P. ginseng berry extract (PGBE) according to the partial ripe (PR), ripe(R) and fully ripe (FR) stage. Lipid accumulation of PGBE was examined by measuring triglyceride content and Oil-Red O staining. These results suggested that the FR stage of PGBE decrease in lipid accumulation during adipocyte differentiation and the amount of threonine, asparagine, fumarate, tyraine, tyrosine, and phenylalanine increased with longer ripening of ginseng berries. Metabolite profiling of P. ginseng was identified by 1H NMR spectra. P. ginseng extract efficiently inhibits adipogenesis in 3 T3-L1 adipocytes concluded that the P. ginseng has the antiobesity properties.BMC Complementary and Alternative Medicine 11/2014; 14(1):455. · 1.88 Impact Factor